Product news from the 01/16/07 news brief

Share this article:
Victory Pharma has inked a deal with Hi-Tech Pharmacal for exclusive US commercial license rights to its Naprelan (naproxen sodium) formulation for the treatment of rheumatoid arthritis. The product will be marketed through Victory’s physician-based field sales force deployed throughout the US with plans for sales force expansion under way. Victory’s promotion of Naprelan is expected to begin during the first quarter of 2007. Acorda Therapeutics said it has completed the expansion of its sales force to 65 people, 52 of whom are area business managers calling on specialists and primary care physicians. The Acorda sales team promotes Zanaflex Capsules (tizanidine hydrochloride), a short-acting drug for the management of spasticity. For 2005, Acorda reported shipments of Zanaflex to wholesalers at $18.6 million, using its pilot sales force of 14 professionals. In March 2006, the company expanded its sales force to 32. Shipments to wholesalers increased to $31 million. Galderma Laboratories announced the availability of a new MetroGel (metronidazole) Topical Gel kit for the topical treatment of the inflammatory lesions of rosacea.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.